Abingworth oversubscribed at $465m for new life sciences fund Abingworth Bioventures 8Written by: Asante Capital | Date: 03 February 2021
Asante Capital are thrilled to announce the final closing of Abingworth Bioventures 8 (ABV 8) which took place at $465 million, exceeding its target and closing at the hard cap.
Abingworth is a leading international life sciences investment group targeting companies developing innovative therapeutics with potential to significantly improve human health. Abingworth will invest in opportunities in the US, UK and Continental Europe and broadly across multiple stages including seed and early stage, development-stage companies, including VIPEs (Venture Investments in Public Equities), and Clinical Co-development opportunities.
Asante Capital Group acted as global placement advisor for the fundraise.
To read more, please see below: